rethinkPeptides Search
Menu
Study breakdown

Semaglutide Kidney Benefits Across Different Baseline Function Levels

Meta AnalysisStrong evidence
The takeaway

Analysis of semaglutide effects on kidney function across different baseline levels confirms renal benefits regardless of starting kidney status.

Key finding

Analysis of semaglutide effects on kidney function across different baseline levels confirms renal b

What the researchers found

Analysis of semaglutide effects on kidney function across different baseline levels confirms renal benefits regardless of starting kidney status.

Why it matters

Relevant to peptide therapeutics.

The numbers in context

Pooled data from SUSTAIN 6 and PIONEER 6. Subgroups analyzed by baseline HbA1c, blood pressure, BMI, and albuminuria status. Outcome: eGFR slope.

How the study worked

In publication.

Who was studied

Adults with type 2 diabetes and high cardiovascular risk from SUSTAIN 6 and PIONEER 6

What this study cannot tell us

In publication.

How to read the evidence

Based on design.

When this study was published

Published in 2025.

The bigger picture

Advances peptide evidence.

Questions still open

  • Long-term implications?
  • Evidence comparison?
  • Next steps?

Common questions

What does this mean?
Analysis of semaglutide effects on kidney function across different baseline levels confirms renal benefits regardless of starting kidney status.
How reliable?
Consult publication.

Read the original research

Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 40(2), 352-359

Citation

Apperloo, Ellen M; Cherney, David Z I; Kuhlman, Anja Birk; Mann, Johannes F E; Rasmussen, Søren; Rossing, Peter; Tuttle, Katherine R; Vrhnjak, Blaz; Heerspink, Hiddo J L. (2025). Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 40(2), 352-359. https://doi.org/10.1093/ndt/gfae150